Caribou Biosciences
Sinhan Desai is a seasoned professional in the field of pharmacovigilance and risk management, currently serving as the Senior Director of Risk Management and Pharmacovigilance at Caribou Biosciences since June 2025. Prior to this role, Sinhan held the position of Director of Pharmacovigilance/Drug Safety Operations at CARGO Therapeutics from September 2023 to June 2025. Sinhan's experience also includes serving as Senior Manager of Drug Safety and Pharmacovigilance at Intersect ENT, Inc. (now part of Medtronic) from February 2020 to September 2023, and as Sr. Safety Scientist at Proteus Digital Health, Inc. from December 2017 to February 2020. Earlier in the career, Sinhan was a Sr. Safety Specialist at Gilead Sciences from April 2016 to December 2017.
This person is not in any teams
This person is not in any offices
Caribou Biosciences
2 followers
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology and located in Berkeley, CA. The company is developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.